Skip to Main Content

Paper Details

Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease.
Alzheimers Res Ther
29
2022
AD, ARGs, Alzheimer's disease, CDK5, GSK3, PPAR, Pioglitazone, atenolol, cyclin-dependent kinase, febuxostat, glipizide, glycogen synthase kinase 3 beta, human, human microglia cells, insulin, patient, patients, peroxisome proliferator-activated receptor, pioglitazone, susceptibility loci, type 2 diabetes
Author NameAffiliation
Rui ChenVanderbilt University
Rui ChenVanderbilt Genetics Institute, Vanderbilt University Medical Center
James B LeverenzCleveland Clinic Lerner College of Medicine, Case Western Reserve University
James B LeverenzLou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic
Bingshan LiVanderbilt University
Bingshan LiVanderbilt Genetics Institute, Vanderbilt University Medical Center
Lang LiCollege of Medicine, Ohio State University
Lang LiCollege of Medicine, Ohio State University
  • 1 - 8

Datasets

Release 1.2